Allogene therapeutics announces publication of durable response data from phase 1 alpha/alpha2 trials of the allogeneic car t cemacabtagene ansegedleucel/allo-501 in relapsed/refractory large b-cell lymphoma in the journal of clinical oncology

South san francisco, calif., feb. 13, 2025 (globe newswire) -- allogene therapeutics, inc. (nasdaq: allo), a clinical-stage biotechnology company pioneering the development of allogeneic car t (allocar t™) products for cancer and autoimmune disease, today announced the publication of data from its phase 1 alpha and alpha2 clinical studies of cemacabtagene ansegedleucel (cema-cel; formerly allo-501/a) in relapsed/refractory (r/r) large b-cell lymphoma (lbcl) as a rapid communication in the journal of clinical oncology. these results represent the largest dataset of lbcl patients treated with an allogeneic car t product and, with a minimum of two years of follow-up, the longest follow-up to date.
CAR Ratings Summary
CAR Quant Ranking